Jeff Y. L. Lam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jeff Y. L. Lam has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- David Klenerman
University of Cambridge
8 shared publications Yunzhao Wu
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK
5 shared publications- Eleni Dimou
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
3 shared publications - Zengjie Xia
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
3 shared publications Derya Emin
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
2 shared publications- Dorothea Böken
University of Cambridge
2 shared publications
Latest Publications
- Open Access
- 5 February 2026
- Published by Springer Nature in Research Square
Cerebrospinal fluid proteomic signatures reveal APOE genotype-dependent lipid and immune profiles in cognitively unimpaired elderly
Cerebrospinal fluid (CSF) proteomics offers insights into molecular changes in aging and Alzheimer’s disease (AD). Key AD biomarkers, in particular amyloid-β (Aβ) and tau, in CSF are strongly associated with APOE genotype, the strongest genetic risk determinant of AD. To investigate how APOE genotype influences CSF proteome across AD pathology and age, we analyzed 362 neurology-related proteins and established AD biomarkers in CSF from 145 cognitively unimpaired participants in the Mayo Clinic Study of Aging. Importantly, our cohort is uniquely balanced across APOE genotypes, with similar representation of APOE2 carriers, APOE3/3 genotype, and APOE4 carriers. We identified several proteins, including lipid metabolism-related Lp-PLA2 and immune-related ITGAM, with strong APOE genotype-specific association. Notably, meta-analysis confirmed that ITGAM levels were consistently higher in APOE4 compared to APOE2 carriers across multiple cohorts and proteomic platforms. In addition, with increasing amyloid deposition, APOE4 carriers exhibited stronger immune responses, reflected by elevated ITGAM, TNF-α receptors, and IL-6, whereas APOE2 carriers showed attenuated responses. We further observed sex-specific effects among APOE2 carriers, characterized by distinct patterns in amyloid and CXCL11 levels. These findings suggest distinct mechanisms underlying APOE2’s protective and APOE4’s detrimental effects in brain aging and AD, paving for personalized diagnostics and interventions.
- 5 February 2026
- Published by Springer Nature in Research Square
Open AccessCerebrospinal fluid proteomic signatures reveal APOE genotype-dependent lipid and immune profiles in cognitively unimpaired elderly
Cerebrospinal fluid (CSF) proteomics offers insights into molecular changes in aging and Alzheimer’s disease (AD). Key AD biomarkers, in particular amyloid-β (Aβ) and tau, in CSF are strongly associated with APOE genotype, the strongest genetic risk determinant of AD. To investigate how APOE genotype influences CSF proteome across AD pathology and age, we analyzed 362 neurology-related proteins and established AD biomarkers in CSF from 145 cognitively unimpaired participants in the Mayo Clinic Study of Aging. Importantly, our cohort is uniquely balanced across APOE genotypes, with similar representation of APOE2 carriers, APOE3/3 genotype, and APOE4 carriers. We identified several proteins, including lipid metabolism-related Lp-PLA2 and immune-related ITGAM, with strong APOE genotype-specific association. Notably, meta-analysis confirmed that ITGAM levels were consistently higher in APOE4 compared to APOE2 carriers across multiple cohorts and proteomic platforms. In addition, with increasing amyloid deposition, APOE4 carriers exhibited stronger immune responses, reflected by elevated ITGAM, TNF-α receptors, and IL-6, whereas APOE2 carriers showed attenuated responses. We further observed sex-specific effects among APOE2 carriers, characterized by distinct patterns in amyloid and CXCL11 levels. These findings suggest distinct mechanisms underlying APOE2’s protective and APOE4’s detrimental effects in brain aging and AD, paving for personalized diagnostics and interventions.
- Open Access
- 16 June 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (29) , 13435-13448
Detecting alpha-synuclein aggregates with small molecules on single-molecule array
Protein aggregates are promising biomarkers for early diagnosis of neurodegenerative disorders. Single-Molecule Array (SiMoA) is a powerful method to detect these aggregates at ultra-low concentrations in biofluids. Herein, we report a next-generation SiMoA assay using chemically synthesized small molecules, rather than antibodies, to capture alpha-synuclein aggregates, a protein hallmark in Parkinson's Disease and other synucleinopathies. These small molecule-based capturing agents contain aggregate-binding head groups, and a backbone functionalized with a primary amine for bead conjugation in the SiMoA assay. The most promising molecule, BF-79-2, captured recombinant alpha-synuclein aggregates, specifically excluding monomers, at picomolar concentrations. BF-79-2 also captured alpha-synuclein aggregates in human blood. Replacing antibodies with small molecules as capturing agents on the SiMoA platform enhances the assay versatility, since small molecules can be screened in silico and synthesized without laborious molecular biology techniques. The application of small molecules as capturing agents broadens the capabilities of the SiMoA platform, rendering it more adaptable for biomarker discovery and disease diagnostics.
- 16 June 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (29) , 13435-13448
Open AccessDetecting alpha-synuclein aggregates with small molecules on single-molecule array
Protein aggregates are promising biomarkers for early diagnosis of neurodegenerative disorders. Single-Molecule Array (SiMoA) is a powerful method to detect these aggregates at ultra-low concentrations in biofluids. Herein, we report a next-generation SiMoA assay using chemically synthesized small molecules, rather than antibodies, to capture alpha-synuclein aggregates, a protein hallmark in Parkinson's Disease and other synucleinopathies. These small molecule-based capturing agents contain aggregate-binding head groups, and a backbone functionalized with a primary amine for bead conjugation in the SiMoA assay. The most promising molecule, BF-79-2, captured recombinant alpha-synuclein aggregates, specifically excluding monomers, at picomolar concentrations. BF-79-2 also captured alpha-synuclein aggregates in human blood. Replacing antibodies with small molecules as capturing agents on the SiMoA platform enhances the assay versatility, since small molecules can be screened in silico and synthesized without laborious molecular biology techniques. The application of small molecules as capturing agents broadens the capabilities of the SiMoA platform, rendering it more adaptable for biomarker discovery and disease diagnostics.
- Open Access
- 23 May 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-11
Detection of p53 aggregates in plasma of glioma patients
Background: The tumour-suppressor protein p53 can form amyloid aggregates resulting in loss of tumour-suppressing functions and leading to tumour formation. The detection of p53 aggregates in cancer cells has been demonstrated but these aggregates have not been detected in liquid biopsies to date, due to the lack of sufficiently sensitive methods. Methods: We developed an ultrasensitive immunoassay based on the single-molecule array (SiMoA) technology to detect p53 aggregates in plasma, based on antibody capture of the aggregates. We confirmed that the assay detects p53 aggregates using super-resolution imaging. We then investigated the p53 aggregate concentrations in the plasma of 190 pre-surgery glioblastoma (GB) patients and 22 controls using this assay. Results: We found that the plasma p53 aggregate levels are significantly elevated in pre-surgery GB patients’ plasma compared to controls. Longitudinal study further reveals that p53 aggregate levels may increase before GB recurrence and decrease following treatment. We also observed raised p53 aggregate concentrations in the plasma of cancer patients with brain metastases. Conclusions: This study demonstrates the detection of p53 aggregates in liquid biopsies. Our findings highlight the potential of p53 aggregates as a novel biomarker for glioblastoma.
- 23 May 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-11
Open AccessDetection of p53 aggregates in plasma of glioma patients
Background: The tumour-suppressor protein p53 can form amyloid aggregates resulting in loss of tumour-suppressing functions and leading to tumour formation. The detection of p53 aggregates in cancer cells has been demonstrated but these aggregates have not been detected in liquid biopsies to date, due to the lack of sufficiently sensitive methods. Methods: We developed an ultrasensitive immunoassay based on the single-molecule array (SiMoA) technology to detect p53 aggregates in plasma, based on antibody capture of the aggregates. We confirmed that the assay detects p53 aggregates using super-resolution imaging. We then investigated the p53 aggregate concentrations in the plasma of 190 pre-surgery glioblastoma (GB) patients and 22 controls using this assay. Results: We found that the plasma p53 aggregate levels are significantly elevated in pre-surgery GB patients’ plasma compared to controls. Longitudinal study further reveals that p53 aggregate levels may increase before GB recurrence and decrease following treatment. We also observed raised p53 aggregate concentrations in the plasma of cancer patients with brain metastases. Conclusions: This study demonstrates the detection of p53 aggregates in liquid biopsies. Our findings highlight the potential of p53 aggregates as a novel biomarker for glioblastoma.
- Open Access
- 6 November 2024
- Published by Springer Nature in Research Square
Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab
Monoclonal antibodies Aducanumab, Lecanemab, Gantenerumab, and Donanemab have been developed for treatment of Alzheimer’s disease. Here, we have used single-molecule detection techniques and super-resolution imaging to characterise the binding of these antibodies to beta-amyloid aggregates including human post-mortem brain samples. Lecanemab is the best antibody in terms of binding to the small-soluble beta-amyloid aggregates, affinity, aggregate coating, and the ability to bind to post-translationally modified species, explaining its therapeutic success.
- 6 November 2024
- Published by Springer Nature in Research Square
Open AccessSingle-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab
Monoclonal antibodies Aducanumab, Lecanemab, Gantenerumab, and Donanemab have been developed for treatment of Alzheimer’s disease. Here, we have used single-molecule detection techniques and super-resolution imaging to characterise the binding of these antibodies to beta-amyloid aggregates including human post-mortem brain samples. Lecanemab is the best antibody in terms of binding to the small-soluble beta-amyloid aggregates, affinity, aggregate coating, and the ability to bind to post-translationally modified species, explaining its therapeutic success.
- Open Access
- 1 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Which isoforms of apolipoprotein E (apoE) we inherit determine our risk of developing late-onset Alzheimer’s Disease (AD), but the mechanism underlying this link is poorly understood. In particular, the relevance of direct interactions between apoE and amyloid-β (Aβ) remains controversial. Here, single-molecule imaging shows that all isoforms of apoE associate with Aβ in the early stages of aggregation and then fall away as fibrillation happens. ApoE-Aβ co-aggregates account for ~50% of the mass of diffusible Aβ aggregates detected in the frontal cortices of homozygotes with the higher-risk APOE4 gene. We show how dynamic interactions between apoE and Aβ tune disease-related functions of Aβ aggregates throughout the course of aggregation. Our results connect inherited APOE genotype with the risk of developing AD by demonstrating how, in an isoform- and lipidation-specific way, apoE modulates the aggregation, clearance and toxicity of Aβ. Selectively removing non-lipidated apoE4-Aβ co-aggregates enhances clearance of toxic Aβ by glial cells, and reduces secretion of inflammatory markers and membrane damage, demonstrating a clear path to AD therapeutics.
- 1 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessCo-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Which isoforms of apolipoprotein E (apoE) we inherit determine our risk of developing late-onset Alzheimer’s Disease (AD), but the mechanism underlying this link is poorly understood. In particular, the relevance of direct interactions between apoE and amyloid-β (Aβ) remains controversial. Here, single-molecule imaging shows that all isoforms of apoE associate with Aβ in the early stages of aggregation and then fall away as fibrillation happens. ApoE-Aβ co-aggregates account for ~50% of the mass of diffusible Aβ aggregates detected in the frontal cortices of homozygotes with the higher-risk APOE4 gene. We show how dynamic interactions between apoE and Aβ tune disease-related functions of Aβ aggregates throughout the course of aggregation. Our results connect inherited APOE genotype with the risk of developing AD by demonstrating how, in an isoform- and lipidation-specific way, apoE modulates the aggregation, clearance and toxicity of Aβ. Selectively removing non-lipidated apoE4-Aβ co-aggregates enhances clearance of toxic Aβ by glial cells, and reduces secretion of inflammatory markers and membrane damage, demonstrating a clear path to AD therapeutics.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
A Novel Method for Detecting Protein Aggregates Using Plasmonic Sensing
Background: Amyloid‐beta (Aβ) protein aggregates have been implicated in the pathology of Alzheimer’s disease (AD). These aggregates are difficult to characterise due to their small size, requiring very sensitive techniques. Gold Nanoparticles (AuNPs) form plasmonic cavities when in close proximity to a gold surface. The cavity both enhances and scatters incident light, with a resonant wavelength strongly dependent on the size of the cavity. These plasmonic cavities were used to detect and size Aβ aggregates at ultra‐low concentration using darkfield spectroscopy.Methods: AuNPs were coated with the Aβ specific 6E10 capture antibody, incubated with a synthetic aggregate sample, and centrifuged to isolate the AuNPs. They were then placed on a gold surface, and darkfield scattering spectra were obtained. The peak scattering wavelengths for each AuNP were used to produce a histogram of gap sizes, and thus the size distribution of detected protein aggregates.Results: Significant differences were seen in resonant peak position between monomeric samples of Aβ and 24 hour aggregated samples. This allows for easy identification of protein monomer vs fibrillar aggregates. In the case of aggregates, some peaks in the darkfield scattering spectra also appeared strongly polarised, suggesting dimerisation of the AuNPs. This was not present for the case of monomeric sample.Conclusions: With this novel technique it was possible to clearly distinguish between samples of Aβ monomer and aggregates. This approach can likely be expanded to find the range and proportion of aggregate sizes in serum samples to detect the onset of AD. The AuNP dimerisation when Aβ aggregates are present is also interesting, and may serve as further verification of the size or shape of these aggregates.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessA Novel Method for Detecting Protein Aggregates Using Plasmonic Sensing
Background: Amyloid‐beta (Aβ) protein aggregates have been implicated in the pathology of Alzheimer’s disease (AD). These aggregates are difficult to characterise due to their small size, requiring very sensitive techniques. Gold Nanoparticles (AuNPs) form plasmonic cavities when in close proximity to a gold surface. The cavity both enhances and scatters incident light, with a resonant wavelength strongly dependent on the size of the cavity. These plasmonic cavities were used to detect and size Aβ aggregates at ultra‐low concentration using darkfield spectroscopy.Methods: AuNPs were coated with the Aβ specific 6E10 capture antibody, incubated with a synthetic aggregate sample, and centrifuged to isolate the AuNPs. They were then placed on a gold surface, and darkfield scattering spectra were obtained. The peak scattering wavelengths for each AuNP were used to produce a histogram of gap sizes, and thus the size distribution of detected protein aggregates.Results: Significant differences were seen in resonant peak position between monomeric samples of Aβ and 24 hour aggregated samples. This allows for easy identification of protein monomer vs fibrillar aggregates. In the case of aggregates, some peaks in the darkfield scattering spectra also appeared strongly polarised, suggesting dimerisation of the AuNPs. This was not present for the case of monomeric sample.Conclusions: With this novel technique it was possible to clearly distinguish between samples of Aβ monomer and aggregates. This approach can likely be expanded to find the range and proportion of aggregate sizes in serum samples to detect the onset of AD. The AuNP dimerisation when Aβ aggregates are present is also interesting, and may serve as further verification of the size or shape of these aggregates.
- Open Access
- 27 September 2023
- Published by Springer Nature in Nature Protocols
- Vol. 18 (12) , 3975
Author Correction: Constructing a cost-efficient, high-throughput and high-quality single-molecule localization microscope for super-resolution imaging
- 27 September 2023
- Published by Springer Nature in Nature Protocols
- Vol. 18 (12) , 3975
Open AccessAuthor Correction: Constructing a cost-efficient, high-throughput and high-quality single-molecule localization microscope for super-resolution imaging
- Top Cited PapersOpen Access
- 20 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
Soluble α-synuclein aggregates varying in size, structure, and morphology have been closely linked to neuronal death in Parkinson’s disease. However, the heterogeneity of different co-existing aggregate species makes it hard to isolate and study their individual toxic properties. Here, we show a reliable non-perturbative method to separate a heterogeneous mixture of protein aggregates by size. We find that aggregates of wild-type α-synuclein smaller than 200 nm in length, formed during an in vitro aggregation reaction, cause inflammation and permeabilization of single-liposome membranes and that larger aggregates are less toxic. Studying soluble aggregates extracted from post-mortem human brains also reveals that these aggregates are similar in size and structure to the smaller aggregates formed in aggregation reactions in the test tube. Furthermore, we find that the soluble aggregates present in Parkinson’s disease brains are smaller, largely less than 100 nm, and more inflammatory compared to the larger aggregates present in control brains. This study suggests that the small non-fibrillar α-synuclein aggregates are the critical species driving neuroinflammation and disease progression.
- 20 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Top Cited PapersOpen AccessSmall soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
Soluble α-synuclein aggregates varying in size, structure, and morphology have been closely linked to neuronal death in Parkinson’s disease. However, the heterogeneity of different co-existing aggregate species makes it hard to isolate and study their individual toxic properties. Here, we show a reliable non-perturbative method to separate a heterogeneous mixture of protein aggregates by size. We find that aggregates of wild-type α-synuclein smaller than 200 nm in length, formed during an in vitro aggregation reaction, cause inflammation and permeabilization of single-liposome membranes and that larger aggregates are less toxic. Studying soluble aggregates extracted from post-mortem human brains also reveals that these aggregates are similar in size and structure to the smaller aggregates formed in aggregation reactions in the test tube. Furthermore, we find that the soluble aggregates present in Parkinson’s disease brains are smaller, largely less than 100 nm, and more inflammatory compared to the larger aggregates present in control brains. This study suggests that the small non-fibrillar α-synuclein aggregates are the critical species driving neuroinflammation and disease progression.
- 24 August 2022
- Published by Springer Nature in Nature Protocols
- Vol. 17 (11) , 2570-2619
Constructing a cost-efficient, high-throughput and high-quality single-molecule localization microscope for super-resolution imaging
Single-molecule localization microscopy (SMLM) leverages the power of modern optics to unleash ultra-precise structural nanoscopy of complex biological machines in their native environments as well as ultra-sensitive and high-throughput medical diagnostics with the sensitivity of a single molecule. To achieve this remarkable speed and resolution, SMLM setups are either built by research laboratories with strong expertise in optical engineering or commercially sold at a hefty price tag. The inaccessibility of SMLM to life scientists for technical or financial reasons is detrimental to the progress of biological and biomedical discoveries reliant on super-resolution imaging. In this work, we present the NanoPro, an economic, high-throughput, high-quality and easy-to-assemble SMLM for super-resolution imaging. We show that our instrument performs similarly to the most expensive, best-in-class commercial microscopes and rivals existing open-source microscopes at a lower price and construction complexity. To facilitate its wide adoption, we compiled a step-by-step protocol, accompanied by extensive illustrations, to aid inexperienced researchers in constructing the NanoPro as well as assessing its performance by imaging ground-truth samples as small as 20 nm. The detailed visual instructions make it possible for students with little expertise in microscopy engineering to construct, validate and use the NanoPro in <1 week, provided that all components are available.
- 24 August 2022
- Published by Springer Nature in Nature Protocols
- Vol. 17 (11) , 2570-2619
Constructing a cost-efficient, high-throughput and high-quality single-molecule localization microscope for super-resolution imaging
Single-molecule localization microscopy (SMLM) leverages the power of modern optics to unleash ultra-precise structural nanoscopy of complex biological machines in their native environments as well as ultra-sensitive and high-throughput medical diagnostics with the sensitivity of a single molecule. To achieve this remarkable speed and resolution, SMLM setups are either built by research laboratories with strong expertise in optical engineering or commercially sold at a hefty price tag. The inaccessibility of SMLM to life scientists for technical or financial reasons is detrimental to the progress of biological and biomedical discoveries reliant on super-resolution imaging. In this work, we present the NanoPro, an economic, high-throughput, high-quality and easy-to-assemble SMLM for super-resolution imaging. We show that our instrument performs similarly to the most expensive, best-in-class commercial microscopes and rivals existing open-source microscopes at a lower price and construction complexity. To facilitate its wide adoption, we compiled a step-by-step protocol, accompanied by extensive illustrations, to aid inexperienced researchers in constructing the NanoPro as well as assessing its performance by imaging ground-truth samples as small as 20 nm. The detailed visual instructions make it possible for students with little expertise in microscopy engineering to construct, validate and use the NanoPro in <1 week, provided that all components are available.